Therapeutic Substances Regulations (Amendment)

Overview

The Therapeutic Substances Act 1953-1959, enacted by the Parliament of Australia, was designed to regulate the quality and safety of therapeutic substances within the country. This legislation aimed to fill the gap in ensuring that therapeutic substances met certain standards before being made available to the public. In 1961, the Therapeutic Substances Regulations were amended to address specific issues related to the payment for samples of therapeutic substances that did not meet the required standards, as well as to establish a Biological Products Standards Committee and a Therapeutic Substances Standards Committee. These committees were tasked with advising the Minister on the standards and matters relating to the standards of various biological products. The policy objective of these amendments was to enhance the oversight and regulation of therapeutic substances, ultimately aiming to protect public health by ensuring the quality and safety of these products.

Scope and Application

The Therapeutic Substances Regulations 1961, made under the Therapeutic Substances Act 1953-1959, pertain to the governance of therapeutic substances within Australia. These regulations apply to persons and entities involved in the manufacture, supply, or distribution of therapeutic substances, including antibiotics, antigens, antitoxins, blood derivatives, insulin products, sera, toxoids, vaccines, and other biological products. They establish standards and requirements for these substances, ensuring their safety, quality, and efficacy. The regulations have a Commonwealth reach, applying across Australia. They exclude substances not listed in the Act and may be subject to further refinement through subordinate instruments, such as amendments or additional regulations issued under the authority of the Act. Notably, the regulations establish specific committees, including the Biological Products Standards Committee and the Therapeutic Substances Standards Committee, to advise on and enforce standards related to therapeutic substances. These committees are composed of experts in relevant fields and are tasked with advising the Minister on standards and related matters.

Key Provisions

The Therapeutic Substances Regulations 1961 (C1961L00049) amend and introduce several key provisions under the Therapeutic Substances Act 1953-1959. Regulation 16 is amended to clarify that payment for samples of goods will not be made if those goods do not conform to the applicable standard (Regulation 16(2)). Regulation 20 replaces the previous provision with a new regulation establishing the Biological Products Standards Committee (Regulation 20(1)), detailing its composition and functions (Regulation 20(2)-(6)). The composition includes the Director-General, the Director of the National Biological Standards Laboratory, and several experts in relevant fields (Regulation 20(2)). Regulation 21 is amended to modify the Therapeutic Substances Standards Committee's composition by including the Director of the National Biological Standards Laboratory and two experts in Pharmacology or Pharmaceutical Chemistry appointed by the Minister (Regulation 21(2)(a) and (d)). It also provides for the appointment of substitute members and sub-committees (Regulation 21(2A) and (5)). Regulation 22 is amended to specify that the Director-General shall be the chairman of each committee, and the Secretary shall be an officer appointed by the Director-General (Regulation 22(1)). The Regulations impose several obligations on the parties and entities they govern. The Biological Products Standards Committee and the Therapeutic Substances Standards Committee are tasked with advising the Minister on matters related to the standards of various therapeutic substances (Regulation 20(5) and Regulation 21(5)). The Director-General is designated as the chairman of these committees, with the Secretary appointed by the Director-General (Regulation 22(1)). The Minister has the authority to appoint members to these committees, including the ability to appoint substitutes for members who are unable to attend meetings (Regulation 20(4) and Regulation 21(2A)). These committees are also empowered to form sub-committees to investigate and report on specific matters within their purview (Regulation 20(6) and Regulation 21(5)). Breach of the provisions within these Regulations may lead to civil or criminal consequences, although specific offences, penalties, or consequences are not explicitly detailed within the Regulations themselves. The Therapeutic Substances Act 1953-1959, under which these Regulations are made, may outline the potential penalties for non-compliance. Typically, non-compliance with regulations pertaining to therapeutic substances could result in administrative penalties, fines, or legal actions under the Act. Given the nature of the substances involved, significant breaches might also attract criminal penalties, reflecting the importance of adherence to these standards for public health and safety.